Deciphering Receptor Signalling, Efficacy-Tolerability Trade-Off & Optimal Amylin Mechanisms to Translate Amylin Biology into Differentiated, Clinically Meaningful Therapies
The amylin analog space is rapidly expanding in 2026, with new companies entering the field, stealth programs beginning to emerge, and major investment from Roche–Zealand Pharma and AbbVie–Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table, there remains headroom to define best‑in‑class amylin therapeutics, open new indications, and shape how this therapeutic area will deliver differentiated, durable benefit. For companies that get the science right, the competitive upside is significant.
The inaugural Amylin‑Based Therapeutics Summit 2026 arrives at this critical inflection point. This is the first and only industry‑dedicated forum bringing biopharma and academia together to dive deep and explore the full breadth of amylin drug development - from foundational receptor biology to late‑stage clinical strategy. Across two immersive days, learn from and connect with pioneering minds from Novo Nordisk, Eli Lilly, Zealand Pharma, iBio, I2O Therapeutics and emerging innovators who are collectively shaping the field.
The conference provided a unique opportunity to interact with individuals with a broad expertise in diverse areas relevant to optimizing treatment for those affected by obesity and related co-morbidities.
Executive Vice President, Medical Affairs, Aardvark Therapeutics
The size (number of attendees) and length was perfect. It allowed for more interactions and networking. The round tables and break activities also were beneficial for that purpose.
Global Senior VP, Product Development & Regulatory Affairs, Adipo Therpeutics
The topics were great and some speakers were excellent and accessible.
Senior Director, Quantitative Pharmacology & Pharmacometrics, Merck
Explore the Full Event Guide
- See the full amylin-focused agenda, from receptor biology and translational challenges through clinical development and commercialization
- Discover the leading amylin programs and case studies being discussed across monotherapy and combination approaches
- Preview insights from the field’s pioneers and key developers, including the scientists shaping next-generation amylin therapeutics
- Benchmark where the field is heading, from receptor selectivity and tolerability to patient positioning and competitive differentiation
- Share one concise overview internally to help colleagues and decision-makers assess the value of attending
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into the latest advances in amylin drug development, from receptor biology and translational challenges to clinical differentiation, combination strategies and commercial opportunity through presentations, roundtables and panel discussions.
Partner With Us
Position your company alongside leading amylin developers and showcase the tools, technologies and services helping biopharma accelerate next-generation amylin programmes.
Join Amylin Experts
Connect with the scientists, clinicians and decision-makers shaping the future of amylin therapeutics across discovery, preclinical, clinical and commercial development.